Zalicus (ZLCS) Advances Z160 into Phase 2a Trials
Tweet
Share
E-mailGet Alerts ZLCS Hot Sheet
Join SI Premium – FREE
Zalicus Inc. (Nasdaq: ZLCS), reports that it is advancing Z160, its novel, first in class, oral, N-type calcium channel blocker into multiple Phase 2a clinical trials for chronic pain indications. Zalicus has selected the most promising novel, proprietary formulation for clinical use and is planning to initiate two Phase 2a clinical trials with Z160 for the treatment of neuropathic pain; the first of which is expected to begin enrolling patients in the third quarter of 2012.
Zalicus completed Phase 1 pharmacokinetic and safety studies with a number of formulations and has selected the optimal formulation to move into further clinical development. The selected formulation was well tolerated and demonstrated a 6-fold improvement in Z160’s bioavailability compared to the previously studied formulation of Z160.
Zalicus completed Phase 1 pharmacokinetic and safety studies with a number of formulations and has selected the optimal formulation to move into further clinical development. The selected formulation was well tolerated and demonstrated a 6-fold improvement in Z160’s bioavailability compared to the previously studied formulation of Z160.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agenus drug combo shows 33% three-year survival in colorectal cancer
- Hyatt Hotels (H) files mixed shelf
- Novavax's Nuvaxovid wins approval in U.S., EU, Japan for 2026-2027
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
